Ionis Pharmaceuticals (IONS) Debt to Equity (2009 - 2026)

Ionis Pharmaceuticals' Debt to Equity history runs 18 years deep, the most recent figure standing at $0.88 for Q1 2026.

• In Q1 2026, Debt to Equity changed N/A year-over-year to $0.88; the TTM figure through Mar 2026 stood at $0.88 (changed N/A YoY), while the FY2025 annual figure was $0.94, up 965.86% from the prior year.
• Debt to Equity was $0.88 for Q1 2026 at Ionis Pharmaceuticals, down from $0.94 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.02 in Q3 2025 to a low of $0.02 in Q1 2023.
• Historically, Debt to Equity has averaged $0.34 across 5 years, with a median of $0.13 in 2024.
• The sharpest annual moves came in 2023 and 2025: Debt to Equity plunged 79.82% in 2023, then surged 1421.0% in 2025.
• A 5-year view of Debt to Equity shows it stood at $0.03 in 2022, then jumped by 699.23% to $0.22 in 2023, then plunged by 60.4% to $0.09 in 2024, then surged by 965.86% to $0.94 in 2025, then slipped by 6.44% to $0.88 in 2026.
• The last three Debt to Equity figures came in at $0.88 (Q1 2026), $0.94 (Q4 2025), and $1.02 (Q3 2025), per Business Quant data.